Skip to main content
U.S. flag

An official website of the United States government

Milestone 9.O

AD Related Dementias – Specific

Neuroimaging characterization of LBD.

Success Criteria

  • Evaluate existing efforts to develop novel imaging markers of LBD, including the feasibility of implementing current candidate imaging markers in clinical trials.
  • Informed by this evaluation: (i) standardize neuroimaging to facilitate multicenter studies; and (ii) begin at least one new study to validate available and proposed imaging tools for the prodromal diagnosis, diagnosis, and progression of LBD.
  • Support neuroimaging research to develop improved approaches for differential diagnoses of LBD compared to other dementing illnesses in longitudinally followed cohorts ultimately confirmed by autopsy.

Summary of Key Accomplishments

Several NIH-funded studies are working to develop imaging markers for LBD. For example, a recently published study found a particular PET imaging measure could help predict whether an individual exhibiting early signs of cognitive decline would go on to develop AD or dementia with Lewy bodies (DLB). In another study, researchers used MRI to assess iron levels in one part of the brain known as the substantia nigra, and they reported that iron levels tended to increase as the severity of DLB increased.

Further evaluation of elevated iron levels as a useful MRI biomarker for disease progression/severity in DLB in a larger number of individuals with DLB will be conducted via the NIH-funded North American Prodromal Synucleinopathy Consortium for REM Sleep Behavior Disorder.

This information is current as of July 2022.

Research Implementation Area
AD Related Dementias - Specific
In Progress

Accomplishments/Implementation Activities

Funding Initiatives

Research Programs and Resources

Relevant Recommendations

An official website of the National Institutes of Health